Mylan to sell two drugs to get clearance for Meda buy
Drug giant Mylan has agreed to sell rights and assets related to products for treating muscle spasms and epilepsy to satisfy the government’s concerns that its $7.2 billion purchase of rival...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login
to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information:
FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch